immunity News and Research

RSS

NIH awards Sanaria Phase II SBIR grant to develop genetically attenuated, whole parasite malaria vaccine

Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The three-year award totaling approximately $3 million will support collaborative research by investigators at Sanaria and Columbia University.

23 Feb 2010

NHMRC awards $12.7 million for malaria research

A research program that aims to better understand malaria infection and develop treatments and vaccines for the disease has today been awarded $12.7 million (US$11.5 million) by Australia's National Health and Medical Research Council (NHMRC).

22 Feb 2010

Poor prescription practices among doctors may increase antibiotic resistance

A new paper in the February 17th edition of the journal Molecular Cell describes how exposure to low levels of antibiotics increases mutations in E. coli and Staphylococcus bacteria hundreds of times more than normal, making the creation of drug-resistant strains more likely.

19 Feb 2010

Research on mosquito genes could be used for disease control measures

By unraveling the mysteries that exist within the molecular composition of mosquitoes, a team of Kansas State University researchers is trying to discover how the insects survive a parasite that causes malaria in humans.

17 Feb 2010

Researchers use new strategy to develop cancer vaccines

Researchers at National Jewish Health and the University of Colorado School of Medicine have used a new strategy to develop cancer vaccines that are remarkably effective in mice. In the February 16 issue of the Proceedings of the National Academy of Sciences, Kimberly Jordan, PhD, Jill Slansky, PhD, and John Kappler, PhD, report that 100 percent of the mice vaccinated with a peptide they developed remained alive and tumor-free for at least 60 days after inoculation with colon cancer cells.

17 Feb 2010

ITS secures £8.65M Series-A equity funding round extension to fund synthetic flu vaccine study

Immune Targeting Systems (ITS) Limited (“ITS”), one of the leading developers of synthetic vaccines for mutating viruses, today announced it had secured a Series-A equity funding round extension for £8.65m which brings the total Series A financing to £13.15m. The company’s key investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital (France) are all participating. The round will be kept open until mid-2010 for new potential investors to invest.

17 Feb 2010

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Oncogenic retroviruses are a particular family of viruses that can cause some types of cancer. Thierry Heidmann and his colleagues in the CNRS-Institut Gustave Roussy-Université Paris Sud 11 "Rétrovirus endogènes et éléments rétroïdes des eucaryotes supérieurs" Laboratory have studied these viruses. They have identified a "virulence factor" that inhibits the host immune response and allows the virus to spread throughout the body.

16 Feb 2010

Proteins found in intestines can recognize and kill bacteria that have human blood type molecules

A set of proteins found in our intestines can recognize and kill bacteria that have human blood type molecules on their surfaces, scientists at Emory University School of Medicine have discovered.

15 Feb 2010

Rate of seasonal flu vaccination doubles national average at Johns Hopkins East Baltimore medical campus

A campaign that makes seasonal flu vaccinations for hospital staff free, convenient, ubiquitous and hard to ignore succeeds fairly well in moving care providers closer to a state of "herd" immunity and protecting patients from possible infection transmitted by health care workers, according to results of a survey at The Johns Hopkins Hospital.

12 Feb 2010

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

A leading immunology research institute has validated the long-held and controversial hypothesis that antibodies - usually the "good guys" in the body's fight against viruses - instead contribute to severe dengue virus-induced disease, the La Jolla Institute for Allergy & Immunology announced today. The finding has major implications for the development of a first-ever vaccine against dengue virus, a growing public health threat which annually infects 50 to 100 million people worldwide, causing a half million cases of the severest form.

12 Feb 2010

Nurse files anonymous complaint with medical board against doctor: Jury hears evidence over misuse of complaint process

Today a jury in West Texas is hearing evidence that a nurse, acting in bad faith, tried to run a doctor out of town by filing an anonymous complaint with the Texas Medical Board. The case is Texas v. Mitchell, No. 5612 (Andrews County, Texas, presiding Judge Jim Rex).

11 Feb 2010

CINJ researchers develop new vaccine strategy for pancreatic cancer

More than 42,500 people in the United States were diagnosed with pancreatic cancer last year and nearly 35,200 died from the disease, according to The American Cancer Society.

11 Feb 2010

Whooping cough vaccine may be losing its punch: study

Vaccination programs against whooping cough may not be fully effective because the bacteria that cause the disease have evolved new strains, a new study has found.

9 Feb 2010

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and Tulane University, today announced a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF), an effort that will generate an additional $800,000 in contract revenue for Corgenix over the life of the contract.

9 Feb 2010

Novavax announces new data from trivalent seasonal influenza VLP vaccine study

Novavax, Inc. announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains.

9 Feb 2010

Early stage trial finds malaria vaccine effectively protected young children, study says

An experimental vaccine was found to effectively protect young children from malaria in Mali, Reuters reports. According to the news service, "The vaccine, which uses an immune system booster called an adjuvant from British drugmaker GlaxoSmithKline, targets the malaria parasite as it is actively infecting red blood cells and causing fever and illness" (Steenhuysen, 2/3).

5 Feb 2010

Ganeden Biotech, Pathway International announce partnership to distribute GanedenBC30

Ganeden Biotech Inc., maker of the patented probiotic strain GanedenBC30®, today announced a partnership with Pathway International Pty Ltd. to exclusively distribute GanedenBC30 in all Australian and New Zealand markets.

4 Feb 2010

DNA variants in mother and fetus can increase risk of preterm labor

Researchers at the National Institutes of Health have identified DNA variants in mothers and fetuses that appear to increase the risk for preterm labor and delivery.

4 Feb 2010

New vaccine to prevent malaria infection shown promise to protect young children

A new vaccine to prevent the deadly malaria infection has shown promise to protect the most vulnerable patients - young children - against the disease, according to an international team of researchers led by the University of Maryland School of Medicine's Center for Vaccine Development (CVD) and the Malaria Research and Training Center at the University of Bamako in Mali, West Africa.

4 Feb 2010

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

2 Feb 2010

immunity News and Research

NIH awards Sanaria Phase II SBIR grant to develop genetically attenuated, whole parasite malaria vaccine

NHMRC awards $12.7 million for malaria research

Poor prescription practices among doctors may increase antibiotic resistance

Research on mosquito genes could be used for disease control measures

Researchers use new strategy to develop cancer vaccines

ITS secures £8.65M Series-A equity funding round extension to fund synthetic flu vaccine study

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Proteins found in intestines can recognize and kill bacteria that have human blood type molecules

Rate of seasonal flu vaccination doubles national average at Johns Hopkins East Baltimore medical campus

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

Nurse files anonymous complaint with medical board against doctor: Jury hears evidence over misuse of complaint process

CINJ researchers develop new vaccine strategy for pancreatic cancer

Whooping cough vaccine may be losing its punch: study

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Novavax announces new data from trivalent seasonal influenza VLP vaccine study

Early stage trial finds malaria vaccine effectively protected young children, study says

Ganeden Biotech, Pathway International announce partnership to distribute GanedenBC30

DNA variants in mother and fetus can increase risk of preterm labor

New vaccine to prevent malaria infection shown promise to protect young children

Cytheris broadens patent protection for recombinant human interleukin-7

Industry Focus eBook - Cell biology (5th edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News